Regional News Archives - Page 83 of 190 - Journal for Clinical Studies

Current Edition

Regional News

Pacira boosts non-opioid pain portfolio via $450M Flexion buy, with more CVR payments to come

Delivering postsurgical analgesic Exparel to blockbuster land is no longer enough for Pacira BioSciences’ appetite. The company is now reaching for its mergers and ac...

13 October 2021 Regional News CVR | Flexion

Continue Reading →

Regional News

Eyes itching from allergies? Ocular’s Dextenza wins FDA approval as first monthly implant

Patients with itchy eyes caused by allergic inflammation often take eye drops multiple times per day. Thanks to an FDA approval, a monthly insert into the canaliculus...

13 October 2021 Regional News allergic inflammation | Dextenza

Continue Reading →

Regional News

Merck and Ridgeback’s molnupiravir will be ‘complementary, but not a competitor’ to COVID-19 vaccines: analyst

What do Merck and Ridgeback’s eye-opening data, recently released for its antiviral molnupiravir on high-risk COVID-19 patients, mean for manufacturers of vaccines? ...

6 October 2021 Regional News antiviral molnupiravir | COVID-19

Continue Reading →

Regional News

As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it...

6 October 2021 Regional News AbbVie | Botox

Continue Reading →

Regional News

Gilead’s Kite enters leukemia with Tecartus FDA approval, overlapping Novartis’ CAR-T rival Kymriah

Gilead Sciences’ Kite Pharma has expanded its second CAR-T cell therapy, Tecartus, into a leukemia market that overlaps a Novartis territory for Kymirah. The FDA cle...

6 October 2021 Regional News CAR-T cell therapy | Gilead Sciences’ Kite Pharma

Continue Reading →

Regional News

Racing rival Pfizer, Merck’s Vaxneuvance makes its case for an FDA approval in children

Time is of the essence for Merck as the company races with rival Pfizer to gain an FDA approval for its next-generation pneumococcal vaccine in children. The longer ...

6 October 2021 Regional News children | FDA

Continue Reading →

Regional News

Researchers retract preprint study that miscalculated higher heart inflammation risk for Moderna, Pfizer COVID vaccines

In the past few weeks, anti-vaxxers have rallied behind a nonpeer-reviewed study by a group of Canadian researchers as evidence against COVID-19 vaccines. Turns out, ...

6 October 2021 Regional News COVID-19 | heart inflammation

Continue Reading →

Regional News

Biohaven’s Nurtec, with dual migraine approvals, hits $136M in quarterly sales and leads the pack in market share

Biohaven's migraine drug Nurtec ODT has been on a roll since becoming the first medicine to win a dual FDA approval to both treat and prevent migraines. Now, the comp...

6 October 2021 Regional News anti-CGRP | Biohaven

Continue Reading →

Regional News

GlaxoSmithKline relocates US operations in Philadelphia, North Carolina as COVID-19 cuts its office space needs

Many companies have shifted their way of working amid COVID-19. Adjusting to how work is done these days, GlaxoSmithKline is downsizing its office footprint in the U....

6 October 2021 Regional News biopharma | Excision BioTherapeutics

Continue Reading →

Regional News

Bristol Myers Squibb previews new ‘transformation’ corporate brand campaign at annual global patients’ event

Bristol Myers Squibb’s new corporate campaign celebrates transformation—of science, the pharma industry and patients’ lives. It’s the pharma’s first corporate campaig...

29 September 2021 Regional News Bristol Myers Squibb | patient

Continue Reading →